Effects of growth factors and receptor blockade on gastrointestinal cancer
- 1 August 2004
- Vol. 53 (8) , 1059-1063
- https://doi.org/10.1136/gut.2003.038620
Abstract
The advent of recombinant peptide technology offers the potential to use one or several peptides to treat a variety of gastrointestinal conditions. However, although cell culture and animal models have shown proof of concept, we are still at a relatively early stage in translating their use to standard clinical practice. Similarly, peptide and non-peptide antagonists of growth factor receptors show great potential as novel antichemotherapy agents. However, their actual place in clinical practice has yet to be established.Keywords
This publication has 34 references indexed in Scilit:
- Epidermal growth factor reduces multiorgan failure induced by thioacetamideGut, 2001
- Combinatorial chemoprevention of intestinal neoplasiaNature Medicine, 2000
- Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colonGut, 2000
- Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.2000
- EGF receptorThe International Journal of Biochemistry & Cell Biology, 1999
- The Epidermal Growth Factor Receptor and Its Inhibition in Cancer TherapyPharmacology & Therapeutics, 1999
- Acromegaly, colonic polyps and carcinomaClinical Endocrinology, 1997
- Comparison of the Effects of Transforming Growth Factor α and Epidermal Growth Factor on Gastrointestinal Proliferation and Hormone ReleaseDigestion, 1996
- The Effect of Epidermal Growth Factor Mouthwash on Cytotoxic-Induced Oral UlcerationAmerican Journal of Clinical Oncology, 1995
- Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptorNature, 1995